Alasdair Macdonald

IQVIA Clinical AB delivers information and technology solutions for healthcare purposes. It specializes in primary care, hospital, and specialist products. The company was founded in 1984 and is headquartered in Solna, Sweden.

Q Squared Solutions (Quest) Ltd. provides diagnostic services for high cholesterol, HIV, allergies, cancers, and other health conditions. The firm's laboratory in the UK serves both doctors and hospitals affiliated with the National Health Service as well as private practices and hospitals, other testing labs, corporations, government agencies, and prisons. The company was founded on April 14, 1999 and is headquartered in Hounslow, the United Kingdom.

IQVIA IES European Holdings provide investment services. The company was founded on November 21, 1996 and is headquartered in Reading, the United Kingdom.

Founded in 2015, Q Squared Solutions Ltd. is a laboratory services provider for the pharmaceutical and biotechnology industries. Part of IQVIA Holdings, Inc., the company is based in Reading, UK.

Founded in 2015, Q Squared Solutions China Ltd. is a biotechnology research and British development company. Part of IQVIA Holdings, Inc., the company is based in Reading, UK.

IQVIA Ltd. provides professional services, information and partnering solutions. The firm serves its services to pharmaceutical, biotechnology, medical device and healthcare industries. It also provides contract research, sales, marketing, healthcare policy consulting and health information management services. The company was founded by Dennis Barry Gillings in 1995 and is headquartered in Reading, the United Kingdom.

Part of IQVIA Holdings, Inc., IQVIA Biotech Ltd. is a British company that provides medical research. The company is based in Reading, UK. The company was founded in 1997. IQVIA Biotech was acquired by PharmalinkFHI, Inc. on June 09, 2008.

Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom.